Stansberry Venture Technology: Dave Lashmet’s Tiny Tech Stock That Could 6X Your Money

by
Dave Lashmet's Tiny Tech Stock

No matter who’s in office, how long COVID-19 continues, or how the market reacts… one little-known American biotech firm could STILL soar 565% in the next 6 months. Our friends at Stansberry Research break the story below…

The trade picks Dave Lashmet makes in his high-end biotech venture capital service have produced gains as high as 1,139% for his readers.

But a massive gain like that almost always takes some time to play out.

We’re talking years… not months.

That’s why the small American biotech firm Dave Lashmet is currently recommending might be THE most time-sensitive opportunity he has ever recommended.

This stock looks like it’s election-proof, pandemic-proof, AND crash-proof.

Why?

Because the tech they’ve quietly developed could slow down the global pandemic.

This tech has NOTHING to do with masks, cleaning products, or vaccines… which is why this company is practically invisible to investors.

Dave Lashmet now believes that this could be the single most profitable stock of 2020 and 2021…

And an upcoming announcement from the company could trigger a potential 565% profit for investors within just 6 months.

But every second counts for your chance to maximize gains…

See Dave Lashmet’s evidence for yourself and get the critical details right here.

Photo of author
Mark Winkel is a U.S.-based author and entrepreneur who lives in the greater New York City area. He studied marketing at the University of Washington and started actively investing in 2017. His approach to the markets blends fundamental research with technical chart analysis, and he concentrates on both swing trades and longer-term positions. Mark's mission is to share tips and strategies at Steady Income to help everyday people make smarter money moves. Mark is all about making finance easier to understand — whether you're just starting out or have been trading for years.

You may also like these posts...

Brad Thomas Wide Moat Confidential Review

Wide Moat Confidential Review: Is Brad Thomas Service Legit?

Is Brad Thomas Wide Moat Confidential worth the hype? Find out in this comprehensive review that covers all the pros and cons of this trading program.
Biotech Stocks Could Soar

Dave Lashmet Triple Play Research – Which Biotech Stocks Could Soar 100%?

Stansberry Venture Technology editor Dave Lashmet has spent more than two decades parsing the data to identify small-cap biotech stocks with big upside potential. And he knows that by focusing on a handful of common-sense medical and investment metrics, you can more easily tell the winners from the losers... and get in before Big Pharma catches on.